Cover Image
市場調查報告書

免疫血液學的診斷檢驗:醫療設備的開發平台評估

Immunohaematology Diagnostic Tests - Medical Devices Pipeline Assessment, 2017

出版商 GlobalData 商品編碼 543305
出版日期 內容資訊 英文 105 Pages
訂單完成後即時交付
價格
Back to Top
免疫血液學的診斷檢驗:醫療設備的開發平台評估 Immunohaematology Diagnostic Tests - Medical Devices Pipeline Assessment, 2017
出版日期: 2017年08月04日 內容資訊: 英文 105 Pages
簡介

本報告提供免疫血液學的診斷檢驗的開發中產品調查分析,作的主要企業,進行中的臨床試驗相關資訊等在各開發階段比較分析為焦點,開發中產品的開發中也包含,提供著有系統的資訊。

第1章 目錄

第2章 簡介

  • 免疫血液學的診斷檢驗概要

第3章 開發中的產品

  • 免疫血液學的診斷檢驗 - 開發中產品:各開發階段
  • 免疫血液學的診斷檢驗 - 開發中產品:各市場區隔
  • 免疫血液學的診斷檢驗 - 開發中產品:各地區
  • 免疫血液學的診斷檢驗 - 開發中產品:各法規
  • 免疫血液學的診斷檢驗 - 開發中產品:各核准預定日

第4章 免疫血液學的診斷檢驗 - 正在開發的開發中產品:各企業

  • 免疫血液學的診斷檢驗企業 - 開發中產品:各開發階段
  • 免疫血液學的診斷檢驗 - 開發中產品:各開發階段

第5章 免疫血液學的診斷檢驗企業與產品概要

  • AbSorber AB
  • Amity University
  • Arizona State University
  • Haemonetics Corp
  • Immucor, Inc.
  • Ortho-Clinical Diagnostics Inc
  • Quotient Limited
  • TBG Diagnostics Ltd
  • TheraDiag SA
  • Transfusion & Transplantation Technologies (暫停中)

第6章 免疫血液學的診斷檢驗 - 最近的趨勢

第7章 附錄

目錄
Product Code: GDME0408EPD

GlobalData's Medical Devices sector report, "Immunohaematology Diagnostic Tests - Medical Devices Pipeline Assessment, 2017" provides an overview of Immunohaematology Diagnostic Tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Immunohaematology Diagnostic Tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope:

  • Extensive coverage of the Immunohaematology Diagnostic Tests under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Immunohaematology Diagnostic Tests and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy:

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Immunohaematology Diagnostic Tests under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Immunohaematology Diagnostic Tests Overview

3. Products under Development

  • 3.1. Immunohaematology Diagnostic Tests - Pipeline Products by Stage of Development
  • 3.2. Immunohaematology Diagnostic Tests - Pipeline Products by Segment
  • 3.3. Immunohaematology Diagnostic Tests - Pipeline Products by Territory
  • 3.4. Immunohaematology Diagnostic Tests - Pipeline Products by Regulatory Path
  • 3.5. Immunohaematology Diagnostic Tests - Pipeline Products by Estimated Approval Date

4. Immunohaematology Diagnostic Tests - Pipeline Products under Development by Companies

  • 4.1. Immunohaematology Diagnostic Tests Companies - Pipeline Products by Stage of Development
  • 4.2. Immunohaematology Diagnostic Tests - Pipeline Products by Stage of Development

5. Immunohaematology Diagnostic Tests Companies and Product Overview

  • 5.1. AbSorber AB Company Overview
    • 5.1.1. AbSorber AB Pipeline Products & Ongoing Clinical Trials Overview
  • 5.2. Amity University Company Overview
    • 5.2.1. Amity University Pipeline Products & Ongoing Clinical Trials Overview
  • 5.3. Arizona State University Company Overview
    • 5.3.1. Arizona State University Pipeline Products & Ongoing Clinical Trials Overview
  • 5.4. Haemonetics Corp Company Overview
    • 5.4.1. Haemonetics Corp Pipeline Products & Ongoing Clinical Trials Overview
  • 5.5. Immucor, Inc. Company Overview
    • 5.5.1. Immucor, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.6. Ortho-Clinical Diagnostics Inc Company Overview
    • 5.6.1. Ortho-Clinical Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.7. Quotient Limited Company Overview
    • 5.7.1. Quotient Limited Pipeline Products & Ongoing Clinical Trials Overview
  • 5.8. TBG Diagnostics Ltd Company Overview
    • 5.8.1. TBG Diagnostics Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • 5.9. TheraDiag SA Company Overview
    • 5.9.1. TheraDiag SA Pipeline Products & Ongoing Clinical Trials Overview
  • 5.10. Transfusion & Transplantation Technologies (Inactive) Company Overview
    • 5.10.1. Transfusion & Transplantation Technologies (Inactive) Pipeline Products & Ongoing Clinical Trials Overview

6. Immunohaematology Diagnostic Tests - Recent Developments

  • 6.1. Jul 28, 2017: Grifols increases its revenues by 12.3% to EUR 2,192 million driven by growth of its main divisions
  • 6.2. Jul 25, 2017: Theradiag: Further Strong Sales Growth in the First Half of 2017: +9%
  • 6.3. Jun 22, 2017: Haemonetics Announces Formation of Scientific Advisory Council
  • 6.4. May 22, 2017: Quotient Reports Continued Progress on the Commercial Scale-up of MosaiQ and Fourth Quarter and Fiscal Year 2017 Financial Results
  • 6.5. May 08, 2017: Haemonetics Reports 4th Quarter and Fiscal Year 2017 Results and Provides Fiscal 2018 Guidance
  • 6.6. May 04, 2017: Bio-Rad Reports First-Quarter 2017 Financial Results
  • 6.7. May 03, 2017: Bioscience Division sales increase 15% to drive Grifols' revenue growth by 11% to Euros 1,062 million
  • 6.8. Apr 27, 2017: THERADIAG Announces First-quarter 2017 Revenues
  • 6.9. Apr 27, 2017: Theradiag: First-Quarter 2017 Revenues
  • 6.10. Apr 03, 2017: U.S. District Judge Grants AllCells Motion for Preliminary Injunction in Lawsuit Against Cepheus Biosciences
  • 6.11. Mar 13, 2017: Bio-Rad Intends to Propose Three New Independent Directors
  • 6.12. Mar 13, 2017: Bio-Rad Initiates Long Term Financial Guidance; Commits to Defining Long Term Capital Allocation Targets and Hosting an Annual Investor Day
  • 6.13. Mar 01, 2017: Appointment of Dominique Costantini and Dominique Takizawa to Theradiag's Board of Directors
  • 6.14. Mar 01, 2017: THERADIAG: Full-year 2016 results
  • 6.15. Feb 28, 2017: Grifols' revenues exceed Euros 4,000 million, driven by +6.5% growth of the Bioscience Division
  • 6.16. Feb 23, 2017: VBio-Rad Reports Fourth-Quarter and Full-Year 2016 Financial Results
  • 6.17. Feb 23, 2017: Bio-Rad Reports Fourth-Quarter and Full-Year 2016 Financial Results
  • 6.18. Feb 09, 2017: Quotient Announces Appointment of Christopher Lindop as Chief Financial Officer
  • 6.19. Feb 06, 2017: Quotient Reports Continued Progress on the Commercial Scale-up of MosaiQ and Third Quarter Fiscal 2017 Financial Results
  • 6.20. Jan 05, 2017: Quotient Reports Positive MosaiQ Results From Performance Evaluation Study for Blood Grouping
  • 6.21. Nov 08, 2016: Sales of the Bioscience Division grow by +6.5%, increasing Grifols' revenues to EUR 2,952 million
  • 6.22. Nov 02, 2016: Quotient Announces CFO Transition
  • 6.23. Nov 01, 2016: Bio-Rad Reports Third-Quarter Currency-Neutral Revenue Growth of 9.1 Percent
  • 6.24. Oct 31, 2016: Quotient Second Quarter Fiscal 2017 Financial Results
  • 6.25. Oct 31, 2016: Quotient Reports Continued Progress on the Commercial Scale-up of MosaiQ and Second Quarter Fiscal 2017 Financial Results
  • 6.26. Oct 27, 2016: Catherine M. Burzik Joins Haemonetics Board of Directors
  • 6.27. Oct 24, 2016: Immucor Announces CE Mark in Europe for NEO Iris; Next Generation, Fully Automated Instrument for Transfusion Medicine
  • 6.28. Oct 20, 2016: AllCells Announces New Vice President, Manufacturing Operations
  • 6.29. Oct 13, 2016: THERADIAG: Very strong revenue growth at end-September 2016: +31%
  • 6.30. Sep 14, 2016: THERADIAG: First-half 2016 Revenues and Results
  • 6.31. Aug 08, 2016: Quotient Reports Further Progress on the Commercial Scale-up of MosaiQ and First Quarter Fiscal 2017 Financial Results

7. Appendix

  • 7.1. Methodology
  • 7.2. About GlobalData
  • 7.3. Contact Us
  • 7.4. Disclaimer

List of Tables

  • Table 1: Immunohaematology Diagnostic Tests - Pipeline Products by Stage of Development
  • Table 2: Immunohaematology Diagnostic Tests - Pipeline Products by Segment
  • Table 3: Immunohaematology Diagnostic Tests - Pipeline Products by Territory
  • Table 4: Immunohaematology Diagnostic Tests - Pipeline Products by Regulatory Path
  • Table 5: Immunohaematology Diagnostic Tests - Pipeline Products by Estimated Approval Date
  • Table 6: Immunohaematology Diagnostic Tests Companies - Pipeline Products by Stage of Development
  • Table 7: Immunohaematology Diagnostic Tests - Pipeline Products by Stage of Development
  • Table 8: AbSorber AB Pipeline Products & Ongoing Clinical Trials Overview
  • Table 9: ABO Diagnostic Test - Product Status
  • Table 10: ABO Diagnostic Test - Product Description
  • Table 11: Amity University Pipeline Products & Ongoing Clinical Trials Overview
  • Table 12: Blood Group Testing Kit - Product Status
  • Table 13: Blood Group Testing Kit - Product Description
  • Table 14: Arizona State University Pipeline Products & Ongoing Clinical Trials Overview
  • Table 15: Blood Screening Immunosignaturing - Product Status
  • Table 16: Blood Screening Immunosignaturing - Product Description
  • Table 17: Haemonetics Corp Pipeline Products & Ongoing Clinical Trials Overview
  • Table 18: Blood Typing System - Product Status
  • Table 19: Blood Typing System - Product Description
  • Table 20: Immucor, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 21: NEO Iris - Product Status
  • Table 22: NEO Iris - Product Description
  • Table 23: Ortho-Clinical Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 24: ORTHO AutoVue - Rare Sera Assay - Product Status
  • Table 25: ORTHO AutoVue - Rare Sera Assay - Product Description
  • Table 26: ORTHO BioVue - Rare Sera Assay - Product Status
  • Table 27: ORTHO BioVue - Rare Sera Assay - Product Description
  • Table 28: Quotient Limited Pipeline Products & Ongoing Clinical Trials Overview
  • Table 29: ALBAclone Anti-C beta Reagent - Product Status
  • Table 30: ALBAclone Anti-C beta Reagent - Product Description
  • Table 31: ALBAclone Anti-e beta Reagent - Product Status
  • Table 32: ALBAclone Anti-e beta Reagent - Product Description
  • Table 33: ALBAclone Anti-H Reagent - Product Status
  • Table 34: ALBAclone Anti-H Reagent - Product Description
  • Table 35: ALBAcyte O Adult i Cell Reagent - Product Status
  • Table 36: ALBAcyte O Adult i Cell Reagent - Product Description
  • Table 37: ALBAcyte O RhD VI Reagent Cells - Product Status
  • Table 38: ALBAcyte O RhD VI Reagent Cells - Product Description
  • Table 39: Eluate Kit - Product Status
  • Table 40: Eluate Kit - Product Description
  • Table 41: MosaiQ IH Microarray - Product Status
  • Table 42: MosaiQ IH Microarray - Product Description
  • Table 43: Polyagglutionation Kit - Product Status
  • Table 44: Polyagglutionation Kit - Product Description
  • Table 45: Sensitivity Kit Anti-S, K, e, C - Product Status
  • Table 46: Sensitivity Kit Anti-S, K, e, C - Product Description
  • Table 47: TBG Diagnostics Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 48: HLAssure SE A Locus SBT Kit - Product Status
  • Table 49: HLAssure SE A Locus SBT Kit - Product Description
  • Table 50: HLAssure SE B Locus SBT Kit - Product Status
  • Table 51: HLAssure SE B Locus SBT Kit - Product Description
  • Table 52: HLAssure SE C Locus SBT Kit - Product Status
  • Table 53: HLAssure SE C Locus SBT Kit - Product Description
  • Table 54: HLAssure SE DQB Locus SBT Kit - Product Status
  • Table 55: HLAssure SE DQB Locus SBT Kit - Product Description
  • Table 56: HLAssure SE DRB-EX Locus SBT Kit - Product Status
  • Table 57: HLAssure SE DRB-EX Locus SBT Kit - Product Description
  • Table 58: TheraDiag SA Pipeline Products & Ongoing Clinical Trials Overview
  • Table 59: LTA003 LISA-TRACKER Anti-Adalimumab - Product Status
  • Table 60: LTA003 LISA-TRACKER Anti-Adalimumab - Product Description
  • Table 61: LTC003 LISA-TRACKER Anti-Certolizumab - Product Status
  • Table 62: LTC003 LISA-TRACKER Anti-Certolizumab - Product Description
  • Table 63: LTE003 LISA-TRACKER Anti-Etanercept - Product Status
  • Table 64: LTE003 LISA-TRACKER Anti-Etanercept - Product Description
  • Table 65: LTG003 LISA-TRACKER Anti-Golimumab - Product Status
  • Table 66: LTG003 LISA-TRACKER Anti-Golimumab - Product Description
  • Table 67: LTI003 LISA-TRACKER Anti-Infliximab Assay - Product Status
  • Table 68: LTI003 LISA-TRACKER Anti-Infliximab Assay - Product Description
  • Table 69: LTR003 LISA-TRACKER Anti-Rituximab Assay - Product Status
  • Table 70: LTR003 LISA-TRACKER Anti-Rituximab Assay - Product Description
  • Table 71: LTT003 LISA TRACKER Anti-Tocilizumab Assay - Product Status
  • Table 72: LTT003 LISA TRACKER Anti-Tocilizumab Assay - Product Description
  • Table 73: LTTR003 LISA-TRACKER Anti-Trastuzumab Assay - Product Status
  • Table 74: LTTR003 LISA-TRACKER Anti-Trastuzumab Assay - Product Description
  • Table 75: LTU003 LISA-TRACKER Anti-Ustekinumab Assay - Product Status
  • Table 76: LTU003 LISA-TRACKER Anti-Ustekinumab Assay - Product Description
  • Table 77: Transfusion & Transplantation Technologies (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
  • Table 78: Aegis - Blood Grouping Assay - Product Status
  • Table 79: Aegis - Blood Grouping Assay - Product Description
  • Table 80: Aegis - Anti-A Quantitation In Group O Platelets - Product Status
  • Table 81: Aegis - Anti-A Quantitation In Group O Platelets - Product Description
  • Table 82: Aegis - Antibody Screening And Identification Assay - Product Status
  • Table 83: Aegis - Antibody Screening And Identification Assay - Product Description
  • Table 84: Aegis - Feto-maternal Hemorrhage Assay - Product Status
  • Table 85: Aegis - Feto-maternal Hemorrhage Assay - Product Description
  • Table 86: Aegis - Platelet Cross-match Assay - Product Status
  • Table 87: Aegis - Platelet Cross-match Assay - Product Description
  • Table 88: Aegis - Residual A Quantitation Assay - Product Status
  • Table 89: Aegis - Residual A Quantitation Assay - Product Description
  • Table 90: Aegis - rWBC Quantitation Assay - Product Status
  • Table 91: Aegis - rWBC Quantitation Assay - Product Description
  • Table 92: AEGIS System - Product Status
  • Table 93: AEGIS System - Product Description
  • Table 94: Glossary

List of Figures

  • Figure 1: Immunohaematology Diagnostic Tests - Pipeline Products by Stage of Development
  • Figure 2: Immunohaematology Diagnostic Tests - Pipeline Products by Segment
  • Figure 3: Immunohaematology Diagnostic Tests - Pipeline Products by Territory
  • Figure 4: Immunohaematology Diagnostic Tests - Pipeline Products by Regulatory Path
  • Figure 5: Immunohaematology Diagnostic Tests - Pipeline Products by Estimated Approval Date
Back to Top